{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:45:44Z","timestamp":1786373144454,"version":"build-2736575974"},"reference-count":75,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>\n                      AKI in pregnancy remains a cause of significant fetomaternal mortality and morbidity, particularly in developing countries. Hypertensive complications of pregnancy (preeclampsia\/eclampsia or hemolysis, elevated liver enzymes, and low platelets count syndrome) are the leading cause of AKI in pregnancy worldwide. Thrombotic microangiopathy is another peculiar and devastating cause of AKI in pregnancy. During the last decade, our understanding, and in some cases, our management, of these causes of AKI in pregnancy has dramatically improved. For instance, convincing data have linked pre-eclampsia\/eclampsia to an increase in circulating antiangiogenic factors soluble Flt 1 and endoglin, which induce endothelial cell dysfunction, hypertension, and proteinuria. Several distinct pathogenic mechanisms underlying thrombotic microangiopathy, including thrombotic microangiopathy occurring during pregnancy, have been established. Thrombotic microangiopathy, which can present as hemolytic uremic syndrome or thrombotic thrombocytopenic purpura, can be reclassified in four potentially overlapping subtypes: disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 deficiency-related thrombotic microangiopathy, complement alternative pathway dysregulation-related thrombotic microangiopathy, secondary thrombotic microangiopathy (verotoxin and antiangiogenic drugs), and thrombotic microangiopathy of undetermined mechanism. In most cases, pregnancy is only a precipitating factor for thrombotic microangiopathy. Treatment of thrombotic microangiopathy occurring during pregnancy should be tailored to the underlying pathogenic mechanism: (\n                      <jats:italic toggle=\"yes\">1<\/jats:italic>\n                      ) restoration of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 serum activity in the setting of thrombotic thrombocytopenic purpura through plasma exchanges and in some cases, B cell-depleting therapy and (\n                      <jats:italic toggle=\"yes\">2<\/jats:italic>\n                      ) inhibition of complement alternative pathway activation in atypical hemolytic uremic syndrome using antiC5 blocking antibody (eculizumab).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.13121211","type":"journal-article","created":{"date-parts":[[2012,8,11]],"date-time":"2012-08-11T20:25:39Z","timestamp":1344716739000},"page":"2100-2106","source":"Crossref","is-referenced-by-count":137,"title":["Obstetric Nephrology"],"prefix":"10.2215","volume":"7","author":[{"given":"Fadi","family":"Fakhouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Vercel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Fr\u00e9meaux-Bacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-26-20230811","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/08860221003606265","article-title":"Acute kidney injury in late pregnancy in developing countries","volume":"32","author":"Prakash","year":"2010","journal-title":"Ren Fail"},{"key":"R2-26-20230811","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0002-9378(00)70216-X","article-title":"Eclampsia. VIII. Risk factors for maternal morbidity","volume":"182","author":"Mattar","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"R3-26-20230811","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/pd.2848","article-title":"Uterine artery Doppler and biochemical markers (PAPP-A, PIGF, sFlt-1, P-selectin, NGAL) at 11 + 0 to 13 + 6 weeks in the prediction of late (> 34 weeks) pre-eclampsia","volume":"31","author":"Youssef","year":"2011","journal-title":"Prenat Diagn"},{"key":"R4-26-20230811","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3109\/08860229609047680","article-title":"Is pregnancy-related acute renal failure a disappearing clinical entity?","volume":"18","author":"Stratta","year":"1996","journal-title":"Ren Fail"},{"key":"R5-26-20230811","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/08860220600583658","article-title":"Acute renal failure in pregnancy in a developing country: Twenty years of experience","volume":"28","author":"Prakash","year":"2006","journal-title":"Ren Fail"},{"key":"R6-26-20230811","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/ndt\/gfl761","article-title":"Decreasing incidence of renal cortical necrosis in patients with acute renal failure in developing countries: A single-centre experience of 22 years from Eastern India","volume":"22","author":"Prakash","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R7-26-20230811","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/pgmj.71.834.208","article-title":"Spectrum of renal cortical necrosis in acute renal failure in eastern India","volume":"71","author":"Prakash","year":"1995","journal-title":"Postgrad Med J"},{"key":"R8-26-20230811","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/ki.1980.127","article-title":"Acute renal failure in pregnancy","volume":"18","author":"Gr\u00fcnfeld","year":"1980","journal-title":"Kidney Int"},{"key":"R9-26-20230811","first-page":"642","article-title":"Acute renal failure of obstetric origin","volume":"48","author":"Chugh","year":"1976","journal-title":"Obstet Gynecol"},{"key":"R10-26-20230811","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijgo.2010.06.026","article-title":"Pregnancy-related acute renal failure in eastern India","volume":"111","author":"Arora","year":"2010","journal-title":"Int J Gynaecol Obstet"},{"key":"R11-26-20230811","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(05)17987-2","article-title":"Pre-eclampsia","volume":"365","author":"Sibai","year":"2005","journal-title":"Lancet"},{"key":"R12-26-20230811","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/ki.1988.236","article-title":"Morphometric analysis of pre-eclampsia in women biopsied in pregnancy and post-partum","volume":"34","author":"Packham","year":"1988","journal-title":"Kidney Int"},{"key":"R13-26-20230811","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1067\/mob.2002.120279","article-title":"Acute renal failure complicating severe preeclampsia requiring admission to an obstetric intensive care unit","volume":"186","author":"Drakeley","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"R14-26-20230811","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nm1429","article-title":"Soluble endoglin contributes to the pathogenesis of preeclampsia","volume":"12","author":"Venkatesha","year":"2006","journal-title":"Nat Med"},{"key":"R15-26-20230811","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJMoa055352","article-title":"Soluble endoglin and other circulating antiangiogenic factors in preeclampsia","volume":"355","author":"Levine","year":"2006","journal-title":"N Engl J Med"},{"key":"R16-26-20230811","doi-asserted-by":"crossref","first-page":"28.e1","DOI":"10.1016\/j.ajog.2007.04.010","article-title":"Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy","volume":"197","author":"Salahuddin","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"R17-26-20230811","doi-asserted-by":"crossref","first-page":"23659","DOI":"10.1074\/jbc.272.38.23659","article-title":"Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1\/KDR, is up-regulated by hypoxia","volume":"272","author":"Gerber","year":"1997","journal-title":"J Biol Chem"},{"key":"R18-26-20230811","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.2353\/ajpath.2010.090800","article-title":"Effects of hypoxia-inducible factor-1alpha overexpression in pregnant mice: Possible implications for preeclampsia and intrauterine growth restriction","volume":"177","author":"Tal","year":"2010","journal-title":"Am J Pathol"},{"key":"R19-26-20230811","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1084\/jem.20061022","article-title":"Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction","volume":"203","author":"Girardi","year":"2006","journal-title":"J Exp Med"},{"key":"R20-26-20230811","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm1452","article-title":"Decidual NK cells regulate key developmental processes at the human fetal-maternal interface","volume":"12","author":"Hanna","year":"2006","journal-title":"Nat Med"},{"key":"R21-26-20230811","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1172\/JCI4106","article-title":"Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor","volume":"103","author":"Wallukat","year":"1999","journal-title":"J Clin Invest"},{"key":"R22-26-20230811","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1161\/01.HYP.0000141085.98320.01","article-title":"Oxidative stress and preeclampsia: Rationale for antioxidant clinical trials","volume":"44","author":"Raijmakers","year":"2004","journal-title":"Hypertension"},{"key":"R23-26-20230811","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1600-6143.2010.03156.x","article-title":"Thrombotic microangiopathy after kidney transplantation","volume":"10","author":"Noris","year":"2010","journal-title":"Am J Transplant"},{"key":"R24-26-20230811","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R25-26-20230811","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ncpneph0670","article-title":"Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?","volume":"3","author":"Fakhouri","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"R26-26-20230811","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Hovinga","year":"2010","journal-title":"Blood"},{"key":"R27-26-20230811","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1007\/s00467-010-1606-y","article-title":"Neurological involvement in a child with atypical hemolytic uremic syndrome","volume":"25","author":"Koehl","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"R28-26-20230811","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med"},{"key":"R29-26-20230811","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1106483","article-title":"Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany","volume":"365","author":"Frank","year":"2011","journal-title":"N Engl J Med"},{"key":"R30-26-20230811","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"key":"R31-26-20230811","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"R32-26-20230811","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1055\/s-0030-1262886","article-title":"Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes","volume":"36","author":"Le Quintrec","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"R33-26-20230811","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R34-26-20230811","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1182\/blood-2008-03-144691","article-title":"Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome","volume":"112","author":"Fakhouri","year":"2008","journal-title":"Blood"},{"key":"R35-26-20230811","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"key":"R36-26-20230811","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4049\/jimmunol.1100491","article-title":"Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis","volume":"187","author":"Morigi","year":"2011","journal-title":"J Immunol"},{"key":"R37-26-20230811","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"R38-26-20230811","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2005-03-0848","article-title":"Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases","volume":"106","author":"Fakhouri","year":"2005","journal-title":"Blood"},{"key":"R39-26-20230811","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"R40-26-20230811","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V98.6.1765","article-title":"Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases","volume":"98","author":"Veyradier","year":"2001","journal-title":"Blood"},{"key":"R41-26-20230811","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R42-26-20230811","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2003-01-0193","article-title":"ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients","volume":"102","author":"Vesely","year":"2003","journal-title":"Blood"},{"key":"R43-26-20230811","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood.V98.9.2730","article-title":"Changes in health and disease of the metalloprotease that cleaves von Willebrand factor","volume":"98","author":"Mannucci","year":"2001","journal-title":"Blood"},{"key":"R44-26-20230811","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1701-2163(16)34741-7","article-title":"Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura","volume":"32","author":"Gall","year":"2010","journal-title":"J Obstet Gynaecol Can"},{"key":"R45-26-20230811","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"key":"R46-26-20230811","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/rheumatology\/keq403","article-title":"Safety of rituximab therapy during twins\u2019 pregnancy","volume":"50","author":"Ton","year":"2011","journal-title":"Rheumatology (Oxford"},{"key":"R47-26-20230811","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1537-2995.2004.03422.x","article-title":"Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"44","author":"Vesely","year":"2004","journal-title":"Transfusion"},{"key":"R48-26-20230811","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-8652(199601)51:1<1::AID-AJH1>3.0.CO;2-2","article-title":"Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: A clinical study of 16 pregnancies","volume":"51","author":"Ezra","year":"1996","journal-title":"Am J Hematol"},{"key":"R49-26-20230811","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2141.2010.08558.x","article-title":"ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy","volume":"153","author":"Raman","year":"2011","journal-title":"Br J Haematol"},{"key":"R50-26-20230811","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/01.mbc.0000240918.65306.20","article-title":"Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura","volume":"17","author":"Scully","year":"2006","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R51-26-20230811","first-page":"1017","article-title":"Eculizumab (Alexion)","volume":"3","author":"Kaplan","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"R52-26-20230811","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.molimm.2011.04.014","article-title":"Inhibiting the C5-C5a receptor axis","volume":"48","author":"Woodruff","year":"2011","journal-title":"Mol Immunol"},{"key":"R53-26-20230811","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.2165\/11208300-000000000-00000","article-title":"Eculizumab: A review of its use in paroxysmal nocturnal haemoglobinuria","volume":"71","author":"McKeage","year":"2011","journal-title":"Drugs"},{"key":"R54-26-20230811","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1111\/j.1600-6143.2009.02817.x","article-title":"Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome","volume":"9","author":"Chatelet","year":"2009","journal-title":"Am J Transplant"},{"key":"R55-26-20230811","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1053\/j.ajkd.2009.08.011","article-title":"Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation","volume":"55","author":"Davin","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"R56-26-20230811","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic-uremic syndrome","volume":"360","author":"Gruppo","year":"2009","journal-title":"N Engl J Med"},{"key":"R57-26-20230811","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/TP.0b013e3181ccd80d","article-title":"Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation","volume":"89","author":"Larrea","year":"2010","journal-title":"Transplantation"},{"key":"R58-26-20230811","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01090209","article-title":"Complement inhibitor eculizumab in atypical hemolytic uremic syndrome","volume":"4","author":"Mache","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R59-26-20230811","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic-uremic syndrome","volume":"360","author":"N\u00fcrnberger","year":"2009","journal-title":"N Engl J Med"},{"key":"R60-26-20230811","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.leukres.2008.09.008","article-title":"Paroxysmal nocturnal hemoglobinuria (PNH) and pregnancy in the era of eculizumab","volume":"33","author":"Danilov","year":"2009","journal-title":"Leuk Res"},{"key":"R61-26-20230811","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2010.08258.x","article-title":"Pregnancy in PNH: Another eculizumab baby","volume":"150","author":"Marasca","year":"2010","journal-title":"Br J Haematol"},{"key":"R62-26-20230811","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08099.x","article-title":"The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab","volume":"149","author":"Kelly","year":"2010","journal-title":"Br J Haematol"},{"key":"R63-26-20230811","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1081\/JDI-200031750","article-title":"Maternal and fetal outcomes in HELLP syndrome complicated with acute renal failure","volume":"26","author":"Gul","year":"2004","journal-title":"Ren Fail"},{"key":"R64-26-20230811","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1067\/mob.2000.106975","article-title":"HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome versus severe preeclampsia: Onset at < or =28.0 weeks\u2019 gestation","volume":"183","author":"Haddad","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"R65-26-20230811","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1081\/JDI-100107367","article-title":"The HELLP syndrome, a prospective study","volume":"23","author":"Abraham","year":"2001","journal-title":"Ren Fail"},{"key":"R66-26-20230811","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/0002-9378(93)90043-I","article-title":"Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome)","volume":"169","author":"Sibai","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"R67-26-20230811","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1081\/JDI-100100875","article-title":"Outcome of pregnancies with HELLP syndrome complicated by acute renal failure (1989\u20131999)","volume":"22","author":"Sel\u00e7uk","year":"2000","journal-title":"Ren Fail"},{"key":"R68-26-20230811","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0301-2115(02)00352-4","article-title":"Pathogenesis of acute renal failure associated with the HELLP syndrome: A case report and review of the literature","volume":"108","author":"Abraham","year":"2003","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R69-26-20230811","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/0002-9378(92)91735-S","article-title":"Hepatic histopathologic condition does not correlate with laboratory abnormalities in HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count)","volume":"167","author":"Barton","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"R70-26-20230811","doi-asserted-by":"crossref","first-page":"283.e1","DOI":"10.1016\/j.ajog.2007.10.797","article-title":"Postpartum dexamethasone for women with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: A double-blind, placebo-controlled, randomized clinical trial","volume":"198","author":"Katz","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"R71-26-20230811","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/01443619867182","article-title":"Plasmapheresis in the management of HELLP syndrome","volume":"18","author":"Eckford","year":"1998","journal-title":"J Obstet Gynaecol"},{"key":"R72-26-20230811","doi-asserted-by":"crossref","first-page":"e1001013","DOI":"10.1371\/journal.pmed.1001013","article-title":"Mutations in complement regulatory proteins predispose to preeclampsia: A genetic analysis of the PROMISSE cohort","volume":"8","author":"Salmon","year":"2011","journal-title":"PLoS Med"},{"key":"R73-26-20230811","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/ki.2010.393","article-title":"Targeted inhibition of complement activation prevents features of preeclampsia in mice","volume":"79","author":"Qing","year":"2011","journal-title":"Kidney Int"},{"key":"R74-26-20230811","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2007-01-070631","article-title":"Tissue factor: A link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury","volume":"110","author":"Redecha","year":"2007","journal-title":"Blood"},{"key":"R75-26-20230811","doi-asserted-by":"crossref","first-page":"167.e1","DOI":"10.1016\/j.ajog.2006.10.879","article-title":"Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies","volume":"196","author":"Shamonki","year":"2007","journal-title":"Am J Obstet Gynecol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201212000-00026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:50Z","timestamp":1786369370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201212000-00026"}},"subtitle":["AKI and Thrombotic Microangiopathies in Pregnancy"],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.13121211","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}